Insmed receives FDA approval

Insmed’s Arikayce has become the first drug approved under a novel FDA pathway designed to speed development of antibiotics.

The active component of antibiotic Arikayce is amikacin, a decade-old antibiotic that’s on the WHO’s essential drug list. But instead of administering it intravenously, Insmed created an inhaled formulation to treat Mycobacterium avium complex (MAC) lung disease as part of combo regimen for patients who don't respond to conventional treatment.

Click here to read the entire article.